Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC

Why It Matters

Resuming the trial restores a potential breakthrough therapy for a high‑mortality lung cancer subtype and signals confidence in the safety management of ADCs, influencing both regulatory precedent and investor sentiment.

Key Takeaways

• FDA lifts partial hold on I‑DXd Phase III trial
• EU regulator still maintains clinical hold
• Companies add stricter enrollment and safety monitoring
• ILD risk remains key safety concern for ADCs
• Success could expand Merck‑Daiichi lung cancer pipeline

Pulse Analysis

The partnership between Merck and Daiichi Sankyo represents one of the most advanced collaborations in the antibody‑drug conjugate (ADC) space. Their DXd platform couples a monoclonal antibody with an exatecan payload, delivering targeted DNA damage to cancer cells. Ifinatamab deruxtecan, the ADC under study, showed a 48.2% confirmed objective response in the Phase II IDeate‑Lung01 trial, raising expectations for the larger Phase III IDeate‑Lung02 study that targets relapsed small‑cell lung cancer, a disease with limited therapeutic options and poor prognosis.

Regulatory scrutiny intensified after the FDA detected an unexpected rise in grade‑5 interstitial lung disease (ILD) events, prompting a partial hold on the trial. Merck and Daiichi responded with tighter enrollment criteria, more frequent unblinded safety data reviews, and enhanced investigator training to mitigate pneumonitis risk. While the U.S. agency has now cleared the study to proceed, the European Medicines Agency continues its hold, underscoring divergent risk assessments across markets and the importance of harmonized safety protocols for novel oncology agents.

The lift of the U.S. hold carries significant market implications. It restores momentum for a pipeline that already includes approved ADCs like Enhertu and the newly approved Datroway, reinforcing confidence among investors and partners such as AstraZeneca. Successful navigation of the safety challenges could position I‑DXd as a first‑in‑class option for small‑cell lung cancer, potentially reshaping treatment standards and expanding the commercial footprint of ADC technology across oncology indications. The outcome will also inform future regulatory pathways for high‑risk, high‑reward biologic‑drug conjugates.